Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Delayed Quote. Delayed  - 06/27 08:57:13 pm
65.705 USD   -0.33%
07:35pDJMERCK AND : Says Its Network Was Hit by Global Hack
07:03p MERCK AND : is the target of a massive hack
06:01p Hackers cause disruption in several European countries
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2012 | 02:15pm CEST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media:
Ron Rogers, (908) 423-6449
or
Investors:
Carol Ferguson, (908) 423-4465


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
07:35pDJMERCK AND : Says Its Network Was Hit by Global Hack
07:03p MERCK AND : is the target of a massive hack
06:01p Hackers cause disruption in several European countries
05:26p MERCK AND : says new type of cholesterol drug worked in big study
12:56p MERCK : Provides Update on REVEAL Outcomes Study of Anacetrapib
06/26 BERGENBIO : Awarded NOK 24m from Innovasjon Norge to Support the Clinical Develo..
06/24 MERCK AND : Gilead among drug stocks buoyed by Trumps healthcare plans
06/22 MERCK AND : Premier Inc. Expand Collaboration to Address Chronic Care and Vaccin..
06/21 LEAP THERAPEUTICS : Announces Collaboration with Merck
06/20 GENEXINE : Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Thera..
More news
Sector news : Pharmaceuticals - NEC
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:08p Kala Pharmaceuticals Files For $86 Million IPO
12:37p Merck's Magic Touch Extends To High-Risk Heart Drug
12:11p Merck confirms ransomware compromise
08:25a Merck's anacetrapib reduced incidence of major coronary events in high-risk p..
07:36a Ablynx earns ?2.5M milestone from collaboration partner Merck
Advertisement
Financials ($)
Sales 2017 39 964 M
EBIT 2017 13 664 M
Net income 2017 7 128 M
Debt 2017 3 171 M
Yield 2017 2,84%
P/E ratio 2017 25,38
P/E ratio 2018 19,20
EV / Sales 2017 4,59x
EV / Sales 2018 4,45x
Capitalization 180 302 M
More Financials
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,4 $
Spread / Average Target 5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY11.98%180 958
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER4.80%203 487
SANOFI15.34%123 860
More Results